Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Barry Quart Sells 20,129 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Barry Quart sold 20,129 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $41.51, for a total value of $835,554.79. Following the sale, the director owned 12,546 shares in the company, valued at approximately $520,784.46. This represents a 61.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Kiniksa Pharmaceuticals International Trading Up 0.2%

KNSA stock traded up $0.10 during midday trading on Wednesday, hitting $41.47. The stock had a trading volume of 389,886 shares, compared to its average volume of 600,411. Kiniksa Pharmaceuticals International, plc has a 52 week low of $17.82 and a 52 week high of $42.98. The stock has a 50-day simple moving average of $39.97 and a 200 day simple moving average of $34.74. The firm has a market capitalization of $3.14 billion, a price-to-earnings ratio of 92.16 and a beta of 0.02.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.08). The business had revenue of $180.86 million during the quarter, compared to the consensus estimate of $166.64 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The company’s quarterly revenue was up 61.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.18) EPS. On average, equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Wall Street Analysts Forecast Growth

KNSA has been the subject of a number of analyst reports. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Wells Fargo & Company raised their target price on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. The Goldman Sachs Group increased their price objective on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International has an average rating of “Moderate Buy” and an average price target of $52.00.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of large investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC raised its position in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares during the last quarter. Corebridge Financial Inc. increased its stake in shares of Kiniksa Pharmaceuticals International by 3.6% in the first quarter. Corebridge Financial Inc. now owns 15,979 shares of the company’s stock valued at $355,000 after buying an additional 549 shares in the last quarter. Martingale Asset Management L P increased its stake in shares of Kiniksa Pharmaceuticals International by 1.3% in the first quarter. Martingale Asset Management L P now owns 50,000 shares of the company’s stock valued at $1,111,000 after buying an additional 640 shares in the last quarter. Mariner LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 5.8% in the third quarter. Mariner LLC now owns 13,253 shares of the company’s stock valued at $515,000 after buying an additional 732 shares during the last quarter. Finally, USA Financial Formulas acquired a new position in Kiniksa Pharmaceuticals International during the 3rd quarter worth about $32,000. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.